NCT00408902 2017-11-22
Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
Clinical Trials
8 trialsNCT00379080 2017-04-07
Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00667394 2015-11-05
Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00390468 2014-05-28
Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases
National Cancer Institute (NCI)
Phase 2 Completed
NCT00297921 2013-11-06
A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For or Who Decline Treatment With Standard Induction Therapy
Millennium Pharmaceuticals, Inc.
Phase 1/2 Withdrawn
NCT00904852 2009-05-20
Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme
Millennium Pharmaceuticals, Inc.
Phase 1 Withdrawn
NCT00064584 2009-03-24
Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML)
Millennium Pharmaceuticals, Inc.
Phase 1 Completed
NCT00274248 2008-02-11
MLN518 in Combination With Standard Induction Chemo. for Treatment of Patients With Newly Diagnosed Acute Myelogenous Leukemia
Millennium Pharmaceuticals, Inc.
Phase 1 Completed